Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Protara Therapeutics, Inc. TARA

Healthcare  —  Biotechnology
3.28 (0.07) (2.09%) as of 25 Sep
Market cap
$198.0M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Protara Therapeutics, Inc. (TARA) Business Profile

Updated before January 2025

Company Overview

Protara Therapeutics, Inc. (NASDAQ: TARA) is a clinical-stage biopharmaceutical company dedicated to identifying and advancing transformative therapies for patients with rare and specialty diseases. Founded in 2017 and headquartered in New York City, Protara focuses on addressing unmet medical needs through innovative research and development. The company is led by a team of seasoned executives with extensive experience in the biopharmaceutical industry. Jesse Shefferman serves as the Chief Executive Officer, bringing a wealth of expertise in drug development and commercialization. Other key members of the leadership team include Blaine Davis, Chief Financial Officer, and Dr. Barry P. Flannelly, Chief Operating Officer, who collectively drive the company’s strategic vision and operational excellence.

Core Business Segments

Protara Therapeutics operates primarily in the biopharmaceutical sector, focusing on the development of therapies for rare diseases and oncology. The company’s core business segments include:

Rare Disease Therapies

Protara is committed to addressing rare diseases with significant unmet medical needs. Its lead product candidate, TARA-002, is an investigational therapy based on a biologic product approved in Japan for lymphatic malformations. TARA-002 is being developed for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations, offering hope to patients with limited treatment options.

Oncology

In the oncology segment, Protara is exploring innovative approaches to treat cancers with high unmet needs. The company is leveraging its expertise in biologics to develop targeted therapies that can improve patient outcomes. While oncology is a growing focus area, Protara’s pipeline is still in the early stages of development.

Supportive Care

Protara also focuses on supportive care therapies to enhance the quality of life for patients undergoing treatment for serious illnesses. This includes the development of therapies aimed at addressing complications and side effects associated with existing treatments.

Business Model

Protara Therapeutics operates as a research-driven biopharmaceutical company. Its business model revolves around the following key components:

  • Research and Development (R&D): Protara invests heavily in R&D to discover and develop innovative therapies. The company collaborates with academic institutions, research organizations, and industry partners to advance its pipeline.
  • Clinical Trials: Protara conducts rigorous clinical trials to evaluate the safety and efficacy of its product candidates. These trials are essential for obtaining regulatory approvals and bringing therapies to market.
  • Revenue Generation: As a clinical-stage company, Protara does not yet generate significant revenue from product sales. Instead, it relies on funding from investors, partnerships, and grants to support its operations.
  • Strategic Partnerships: Protara seeks strategic collaborations with other biopharmaceutical companies and research institutions to accelerate the development and commercialization of its therapies.

Strategic Direction

Protara Therapeutics has a clear strategic vision aimed at achieving long-term growth and sustainability. Key elements of its strategic direction include:

  • Pipeline Expansion: The company is focused on expanding its pipeline of therapies for rare diseases and oncology. This includes advancing TARA-002 through clinical trials and exploring additional indications for its use.
  • Regulatory Approvals: Protara is committed to obtaining regulatory approvals for its lead product candidates, enabling it to bring transformative therapies to market.
  • Sustainability Goals: The company aims to integrate sustainability into its operations by minimizing its environmental footprint and promoting ethical practices in clinical research.
  • Global Reach: Protara is exploring opportunities to expand its presence in international markets, ensuring that patients worldwide have access to its therapies.

Competitive Landscape

Protara Therapeutics operates in a highly competitive biopharmaceutical industry. Key competitors include:

  • Rare Disease Companies: Companies like Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, and Alexion Pharmaceuticals are major players in the rare disease space, offering therapies for conditions with limited treatment options.
  • Oncology Biopharma: In the oncology segment, Protara faces competition from established companies such as Bristol-Myers Squibb, Merck, and Novartis, as well as smaller biotech firms developing innovative cancer therapies.
  • Supportive Care Providers: Companies like Amgen and Gilead Sciences also compete in the supportive care market, offering therapies to manage treatment-related complications.

Risk Factors

Protara Therapeutics faces several risks that could impact its operations and financial performance:

  • Regulatory Risks: The company’s success depends on obtaining regulatory approvals for its product candidates. Delays or rejections could hinder its ability to bring therapies to market.
  • Market Dependence: As a clinical-stage company, Protara relies heavily on external funding. Failure to secure additional financing could limit its ability to advance its pipeline.
  • Supply Chain Disruptions: The company depends on third-party manufacturers and suppliers for the production of its therapies. Disruptions in the supply chain could delay clinical trials and commercialization efforts.
  • Competitive Pressure: Intense competition in the biopharmaceutical industry could impact Protara’s market share and profitability.

Recent Developments

Protara Therapeutics has made significant progress in advancing its pipeline and corporate strategy. Recent developments include:

  • Clinical Trial Advancements: The company has initiated Phase 1 and Phase 2 clinical trials for TARA-002, demonstrating its commitment to addressing unmet medical needs.
  • Strategic Partnerships: Protara has entered into collaborations with leading research institutions to accelerate the development of its therapies.
  • Corporate Initiatives: The company has strengthened its leadership team and expanded its board of directors to enhance governance and strategic oversight.
  • Global Developments: The COVID-19 pandemic has posed challenges for clinical trial enrollment and supply chain operations. However, Protara has implemented measures to mitigate these impacts and ensure business continuity.

Investment Considerations

Investors considering Protara Therapeutics should weigh the following factors:

Strengths

  • Innovative Pipeline: Protara’s focus on rare diseases and oncology positions it as a leader in addressing unmet medical needs.
  • Experienced Leadership: The company’s leadership team has a proven track record in drug development and commercialization.
  • Strategic Vision: Protara’s commitment to sustainability and global expansion enhances its long-term growth prospects.

Risks

  • Clinical-Stage Status: As a clinical-stage company, Protara does not yet generate significant revenue, making it reliant on external funding.
  • Regulatory Uncertainty: The success of its product candidates depends on obtaining regulatory approvals, which are not guaranteed.
  • Market Competition: Intense competition from established players could impact Protara’s ability to capture market share.

Conclusion

Protara Therapeutics, Inc. is a promising biopharmaceutical company with a strong focus on rare diseases and oncology. While it faces challenges as a clinical-stage company, its innovative pipeline, experienced leadership, and strategic vision position it for long-term success. As Protara advances its therapies through clinical trials and pursues regulatory approvals, it has the potential to make a significant impact on patients’ lives and deliver value to investors. The company’s commitment to addressing unmet medical needs and expanding its global reach underscores its growth potential in the competitive biopharmaceutical industry.